The role of paclitaxel in the treatment of primary and metastatic brain tumors

M. J. Glantz, M. C. Chamberlain, S. M. Chang, M. D. Prados, B. F. Cole

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The rationale for the use of paclitaxel to treat brain tumors includes impressive activity in a wide array of chemotherapy-resistant solid tumors, in vitro and in vivo evidence of cytotoxicity against primary brain tumors, and a paucity of effective alternative agents. A review of published studies evaluating paclitaxel alone or in combination with other chemotherapeutic agents suggests that paclitaxel alone is not highly active against newly diagnosed or recurrent glioblastoma multiforme. However, additional prospective trials are warranted to evaluate the efficacy of paclitaxel plus conventional cranial irradiation or stereotactic radiosurgery. Single-agent paclitaxel appears to be active against gliomas with an oligodendroglial component and may prove useful both as a component of initial therapy and for recurrent disease. Activity against anaplastic gliomas and brain metastases also should be explored. With radiation, a weekly paclitaxel administration schedule is particularly appealing from pharmacologic, safety, and dose- intensity perspectives. In addition, the dose of paclitaxel must be increased in patients who are concurrently receiving medications that induce the P-450 drug metabolizing system. Primary and metastatic brain tumors constitute a very difficult problem in oncology. Future investigations should be directed at evaluating paclitaxel-based chemotherapy regimens in selected brain tumor types, combining paclitaxel with stereotactic radiosurgery, and determining the importance of other proposed mechanisms of action of paclitaxel (eg, inhibition of angiogenesis and tumor invasion).

Original languageEnglish (US)
Pages (from-to)27-33
Number of pages7
JournalSeminars in Radiation Oncology
Volume9
Issue number2 SUPPL. 1
StatePublished - May 3 1999

Fingerprint

Paclitaxel
Brain Neoplasms
Therapeutics
Radiosurgery
Glioma
Cranial Irradiation
Drug Therapy
Glioblastoma
Neoplasms
Appointments and Schedules
Radiation
Neoplasm Metastasis
Safety
Brain

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Glantz, M. J., Chamberlain, M. C., Chang, S. M., Prados, M. D., & Cole, B. F. (1999). The role of paclitaxel in the treatment of primary and metastatic brain tumors. Seminars in Radiation Oncology, 9(2 SUPPL. 1), 27-33.
Glantz, M. J. ; Chamberlain, M. C. ; Chang, S. M. ; Prados, M. D. ; Cole, B. F. / The role of paclitaxel in the treatment of primary and metastatic brain tumors. In: Seminars in Radiation Oncology. 1999 ; Vol. 9, No. 2 SUPPL. 1. pp. 27-33.
@article{fcbf065c84924175a5636964a20faed7,
title = "The role of paclitaxel in the treatment of primary and metastatic brain tumors",
abstract = "The rationale for the use of paclitaxel to treat brain tumors includes impressive activity in a wide array of chemotherapy-resistant solid tumors, in vitro and in vivo evidence of cytotoxicity against primary brain tumors, and a paucity of effective alternative agents. A review of published studies evaluating paclitaxel alone or in combination with other chemotherapeutic agents suggests that paclitaxel alone is not highly active against newly diagnosed or recurrent glioblastoma multiforme. However, additional prospective trials are warranted to evaluate the efficacy of paclitaxel plus conventional cranial irradiation or stereotactic radiosurgery. Single-agent paclitaxel appears to be active against gliomas with an oligodendroglial component and may prove useful both as a component of initial therapy and for recurrent disease. Activity against anaplastic gliomas and brain metastases also should be explored. With radiation, a weekly paclitaxel administration schedule is particularly appealing from pharmacologic, safety, and dose- intensity perspectives. In addition, the dose of paclitaxel must be increased in patients who are concurrently receiving medications that induce the P-450 drug metabolizing system. Primary and metastatic brain tumors constitute a very difficult problem in oncology. Future investigations should be directed at evaluating paclitaxel-based chemotherapy regimens in selected brain tumor types, combining paclitaxel with stereotactic radiosurgery, and determining the importance of other proposed mechanisms of action of paclitaxel (eg, inhibition of angiogenesis and tumor invasion).",
author = "Glantz, {M. J.} and Chamberlain, {M. C.} and Chang, {S. M.} and Prados, {M. D.} and Cole, {B. F.}",
year = "1999",
month = "5",
day = "3",
language = "English (US)",
volume = "9",
pages = "27--33",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 1",

}

Glantz, MJ, Chamberlain, MC, Chang, SM, Prados, MD & Cole, BF 1999, 'The role of paclitaxel in the treatment of primary and metastatic brain tumors', Seminars in Radiation Oncology, vol. 9, no. 2 SUPPL. 1, pp. 27-33.

The role of paclitaxel in the treatment of primary and metastatic brain tumors. / Glantz, M. J.; Chamberlain, M. C.; Chang, S. M.; Prados, M. D.; Cole, B. F.

In: Seminars in Radiation Oncology, Vol. 9, No. 2 SUPPL. 1, 03.05.1999, p. 27-33.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The role of paclitaxel in the treatment of primary and metastatic brain tumors

AU - Glantz, M. J.

AU - Chamberlain, M. C.

AU - Chang, S. M.

AU - Prados, M. D.

AU - Cole, B. F.

PY - 1999/5/3

Y1 - 1999/5/3

N2 - The rationale for the use of paclitaxel to treat brain tumors includes impressive activity in a wide array of chemotherapy-resistant solid tumors, in vitro and in vivo evidence of cytotoxicity against primary brain tumors, and a paucity of effective alternative agents. A review of published studies evaluating paclitaxel alone or in combination with other chemotherapeutic agents suggests that paclitaxel alone is not highly active against newly diagnosed or recurrent glioblastoma multiforme. However, additional prospective trials are warranted to evaluate the efficacy of paclitaxel plus conventional cranial irradiation or stereotactic radiosurgery. Single-agent paclitaxel appears to be active against gliomas with an oligodendroglial component and may prove useful both as a component of initial therapy and for recurrent disease. Activity against anaplastic gliomas and brain metastases also should be explored. With radiation, a weekly paclitaxel administration schedule is particularly appealing from pharmacologic, safety, and dose- intensity perspectives. In addition, the dose of paclitaxel must be increased in patients who are concurrently receiving medications that induce the P-450 drug metabolizing system. Primary and metastatic brain tumors constitute a very difficult problem in oncology. Future investigations should be directed at evaluating paclitaxel-based chemotherapy regimens in selected brain tumor types, combining paclitaxel with stereotactic radiosurgery, and determining the importance of other proposed mechanisms of action of paclitaxel (eg, inhibition of angiogenesis and tumor invasion).

AB - The rationale for the use of paclitaxel to treat brain tumors includes impressive activity in a wide array of chemotherapy-resistant solid tumors, in vitro and in vivo evidence of cytotoxicity against primary brain tumors, and a paucity of effective alternative agents. A review of published studies evaluating paclitaxel alone or in combination with other chemotherapeutic agents suggests that paclitaxel alone is not highly active against newly diagnosed or recurrent glioblastoma multiforme. However, additional prospective trials are warranted to evaluate the efficacy of paclitaxel plus conventional cranial irradiation or stereotactic radiosurgery. Single-agent paclitaxel appears to be active against gliomas with an oligodendroglial component and may prove useful both as a component of initial therapy and for recurrent disease. Activity against anaplastic gliomas and brain metastases also should be explored. With radiation, a weekly paclitaxel administration schedule is particularly appealing from pharmacologic, safety, and dose- intensity perspectives. In addition, the dose of paclitaxel must be increased in patients who are concurrently receiving medications that induce the P-450 drug metabolizing system. Primary and metastatic brain tumors constitute a very difficult problem in oncology. Future investigations should be directed at evaluating paclitaxel-based chemotherapy regimens in selected brain tumor types, combining paclitaxel with stereotactic radiosurgery, and determining the importance of other proposed mechanisms of action of paclitaxel (eg, inhibition of angiogenesis and tumor invasion).

UR - http://www.scopus.com/inward/record.url?scp=0032958648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032958648&partnerID=8YFLogxK

M3 - Article

C2 - 10210537

AN - SCOPUS:0032958648

VL - 9

SP - 27

EP - 33

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 2 SUPPL. 1

ER -

Glantz MJ, Chamberlain MC, Chang SM, Prados MD, Cole BF. The role of paclitaxel in the treatment of primary and metastatic brain tumors. Seminars in Radiation Oncology. 1999 May 3;9(2 SUPPL. 1):27-33.